Mode
Text Size
Log in / Sign up
Phase 3 Completed N=213 Randomized Health Services Research

Buprenorphine for Prisoners

Heroin Addiction
Source: ClinicalTrials.gov NCT00574067 ↗
Enrolled (actual)
213
Serious AEs
18.0%
Results posted
Apr 2016
Primary outcomePrimary: Number of Days of Heroin Use — 6.0; 6.4; 6.5; 4.0 days
◆ Published Evidence
Emerging
6citations · ~1 / year
Longitudinal analysis of HIV-risk behaviors of participants in a randomized trial of prison-initiated buprenorphine.
Addiction science & clinical practice · 2019 · Open access · Likely link

Summary

This five-year study examines the effectiveness of buprenorphine treatment provided to previously-addicted inmates(N=320; 160 males, 160 females) initiated in prison and continued in the community. The study also examines the extent to which the setting of post-release buprenorphine is provided.It is expected that participants receiving in-prison buprenorphine will have superior outcomes compared to participants who did not receive in-prison buprenorphine.

Linked Publications

  • Longitudinal analysis of HIV-risk behaviors of participants in a randomized trial of prison-initiated buprenorphine.
    Addiction science & clinical practice · 2019 · 6 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Days of Heroin Use
6.0; 6.4; 6.5; 4.0
PRIMARY
Drug Abuse Treatment Entry and Retention in the Community
22; 26; 23; 11
SECONDARY
Number of Days of Cocaine Use
1.1; 4.1; 4.7; 2.7
SECONDARY
Criminal Activity
3.4; 5.4; 3.3; 3.2
SECONDARY
Employment Status
30.0; 29.6; 22.3; 31.4
SECONDARY
HIV Risk Behavior Needle Sharing
2.9; .1; 2.1; .1
SECONDARY
HIV Risk Behavior
59.7; 36.1; 33.3; 50.4

Eligibility Criteria

Inclusion Criteria

  • pre-release prison inmate with 3-6 months remaining until planned release
  • history of heroin dependence(meeting DSM-IV criteria of heroin dependence at the time of incarceration and manifesting physical dependence during the year preceding incarceration
  • suitability for buprenorphine treatment as determined by medical evaluation
  • willingness to participate in the study
  • having a Baltimore address and planning to live in Baltimore after release from prison -

Exclusion Criteria

  • evidence of kidney failure
  • evidence of liver failure
  • history of psychosis
  • having a pending parole hearing
  • unadjudicated charges that could result in additional prison time or transfer to another facility -
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00574067) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search